Effect of Three Regimens of Cholecalciferol Supplementation in Vitamin D Deficiency Among Obese and Non-Obese Women

Presentation Number: SUN 352
Date of Presentation: April 2nd, 2017

Narin NASIROGLU Imga*1, Dilek Berker1, Bulent CAN1 and Serdar Guler2
1Ankara Numune Education and Research Hospital, Ankara, Turkey, 2Hitit University, Faculty of Medicine, Corum, Turkey


Introduction: Vitamin D deficiency is defined as a 25-hydroxyvitamin D [25(OH)D] level below 20 ng/ml. In its treatment, the dose of vitamin D supplementation should provide the plasma levels of 25(OH) D above 30 ng/ml to provide musculoskeletal health and be protective for infectious, autoimmune and cardiovascular diseases. It is known that obese adults (BMI >30 kg/m2) are at high risk for vitamin D deficiency because the body fat sequesters fat-soluble vitamins. We aimed to compare daily oral, weekly oral and monthly intramuscular injection regimens of cholecalciferol (vitamin D3) among obese and non-obese women.

Patients and Methods: In this study, a total of 105 non-obese and 126 obese individuals received three regimens of cholecalciferol randomly. Initially patients were divided into three groups. Group 1; treated with orally daily vitamin D3 supplementation according to 25(OH)D levels (approx. 150 IU/per drop), group 2; orally 50.000 IU of vitamin D3 once a week, group 3; IM 300.000 IU of vitamin D3 per month. Pharmacological cholecalciferol doses were given continuously for three months and then discontinued at the end of third month. All patients are evaluated for serum vitamin D levels before the initiation and at the end of 3 months of treatment, and also three months (sixth month) after withdrawal for Vitamin D treatment.

Results: In non-obese patients oral daily vitamin D3 therapy normalized vitamin D levels in significiantly higher percentage of patients than both weekly oral and intramuscular regimens (94% vs. 55% vs. 64%, respectively; p<0.001 for both). On the other hand in obese patients oral weekly therapy was found successful (83%) while compared to daily oral and IM regimens (83% vs. 63% vs. 71%, respectively; p<0.05) at the third month of treatment. Among all patients (non-obese and obese) serum 25(OH) D levels remained >30 ng/ml in more patients in the oral daily group than oral weekly and IM groups (56% vs. 44% vs. 14%, respectively; p<0.001 for both) at the sixth months.

Discussion: It is estimated that most people in the worldwide are vitamin D deficient. In non-obese orally daily therapy and in obese patients orally weekly cholecalciferol therapy is effective for the raise vitamin D status. Daily administration of orally cholecalciferol is adequate regimen to maintain blood levels of 25(OH) D above to 30 ng/ml in all patients.


Nothing to Disclose: NNI, DB, BC, SG